Utility of Procalcitonin (PCT) and Mid regional pro-Adrenomedullin (MR-proADM) in risk stratification of critically ill febrile patients in Emergency Department (ED). A comparison with APACHE II score

BMC Infectious Diseases

Volumn 12, Issue , 2012, Pages

  Travaglino, Francesco ^a   De Berardinis, Benedetta ^a   Magrini, Laura ^a   Bongiovanni, Cristina ^a   Candelli, Marcello ^b   Silveri, Nicolò G ^b   Legramante, Jacopo ^c   Galante, Alberto ^c   Salerno, Gerardo ^a   Cardelli, Patrizia ^a   Di Somma, Salvatore ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

Author keywords

APACHE II score; Fever; Mid regional pro Adrenomedullin; Procalcitonin

Indexed keywords

MID REGIONAL PROADRENOMEDULLIN; PROADRENOMEDULLIN; PROCALCITONIN; UNCLASSIFIED DRUG;

ADULT; AGED; APACHE; AREA UNDER THE CURVE; ARTICLE; CENTRAL NERVOUS SYSTEM INFECTION; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DISEASE SEVERITY; EMERGENCY WARD; FEMALE; FEVER; GASTROINTESTINAL INFECTION; HOSPITALIZATION; HUMAN; INFECTION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OSTEOMYELITIS; PREDICTION; PROGNOSIS; RESPIRATORY TRACT INFECTION; RISK FACTOR; SEPSIS; SHOCK; SOFT TISSUE INFECTION; URINARY TRACT INFECTION;

ADOLESCENT; ADRENOMEDULLIN; ADULT; AGED; AGED, 80 AND OVER; APACHE; CALCITONIN; CRITICAL ILLNESS; EMERGENCY MEDICAL SERVICES; FEMALE; FEVER; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROGNOSIS; PROTEIN PRECURSORS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84864568681     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-12-184     Document Type: Article

References (45)

1. Limper M, Eeftinck Schattenkerk D, de Kruif MD, van Wissen M, Brandjes DP, Duits AJ, van Gorp EC. One-year epidemiology of fever at the Emergency Department. Neth J Med 2011, 69:124-128.
2. Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I, Neidert S, Fricker T, Blum C, Schild U, Regez K, Schoenenberger R, Henzen C, Bregenzer T, Hoess C, Krause M, Bucher HC, Zimmerli W, Mueller B, . ProHOSP Study Group Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009, 9:1059-1066. ProHOSP Study Group.
3. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. ACCP/SCCM consensus conference committee. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM consensus conference committee. American college of chest physicians/society of critical care medicine. 1992. Chest 2009, 136:e28. 10.1378/chest.09-2267, 20162763.
4. Bossink AW, Groeneveld AB, Thijs LG. Prediction of microbial infection and mortality in medical patients with fever: plasma procalcitonin, neutrophilic elastase-alpha1-antitrypsin, and lactoferrin compared with clinical variables. Clin Infect Dis 1999, 29:398-407. 10.1086/520222, 10476749.
5. Hausfater P, Juillien G, Madonna-Py B, Haroche J, Bernard M, Riou B. Serum procalcitonin measurement as diagnostic and prognostic marker in febrile adult patients presenting to the emergency department. Crit Care 2007, 11:R60. 10.1186/cc5926, 2206417, 17521430.
6. Müller B, Becker KL, Schächinger H, Rickenbacher PR, Huber PR, Zimmerli W, Ritz R. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit Care Med 2000, 28:977-983. 10.1097/00003246-200004000-00011, 10809269.
7. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C reactive proteine levels as markers of bacterial infection: a sistematic review and meta analysis. Clin Infect Dis 2004, 39:206-217. 10.1086/421997, 15307030.
8. Hinson JP, Kapas S, Smith DM. Adrenomedullin, a multifunctional regulatory peptide. Endocr Rev 2000, 21:138-167. Review, 10.1210/er.21.2.138, 10782362.
9. Struck J, Tao C, Morgenthaler NG, Bergmann A. Identification of an Adrenomedullin precursor fragment in plasma of sepsis patients. Peptides 2004, 25:1369-1372. 10.1016/j.peptides.2004.06.019, 15350706.
10. Gori CS, Magrini L, Travaglino F, Di Somma S. Role of biomarkers in patients with dyspnea. Eur Rev Med Pharmacol Sci 2011, 15:229-240. Review.
11. Hausfater P, Brochet C, Freund Y, Charles V, Bernard M. Procalcitonin measurement in routine emergency medicine practice: comparison between two immunoassays. Clin Chem Lab Med 2010, 48:501-504.
12. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985, 13:818-829. 10.1097/00003246-198510000-00009, 3928249.
13. Legget J. Approach to fever or suspected infection in the normal host. Cecil medicine 2007, Sounders Elsevier, Philadelphia, Goldman L, Ausiello D, 23, Cap. 302.
14. De Kruif MD, Limper M, Gerritsen H, Spek CA, Brandjes DP, ten Cate H, Bossuyt PM, Reitsma PH, van Gorp EC. Additional value of procalcitonin for diagnosis of infection in patients with fever at the emergency department. Crit Care Med 2010, 38:457-463. 10.1097/CCM.0b013e3181b9ec33, 20083920.
15. Hirata Y, Mitaka C, Sato K, Nagura T, Tsunoda Y, Amaha K, Marumo F. Increased circulating adrenomedullin, a novel vasodilatory peptide, in sepsis. J Clin Endocrinol Metab 1996, 81:1449-1453. 10.1210/jc.81.4.1449, 8636349.
16. Henderson AR. Assessing test accuracy and its clinical consequences: a primer for receiver operating characteristic curve analysis. Ann Clin Biochem 1993, 30:521-539. Review.
17. Christ-Crain M, Morgenthaler NG, Struck J, Harbarth S, Bergmann A, Müller B. Mid-regional pro-adrenomedullin as a prognostic marker in sepsis: an observational study. Crit Care 2005, 9:R816-R824. 10.1186/cc3885, 1414007, 16356231.
18. Morgenthaler NG, Struck J, Christ-Crain M, Bergmann A, Müller B. Pro-atrial natriuretic peptide is a prognostic marker in sepsis, similar to the APACHE II score: an observational study. Crit Care 2005, 9:R37-R45. 10.1186/cc3015, 1065109, 15693965.
19. Knott JC, Tan SL, Street AC, Bailey M, Cameron P. Febrile adults presenting to the emergency department: outcomes and markers of serious illness. Emerg Med J 2004, 21:170-174. 10.1136/emj.2002.001933, 1726308, 14988341.
20. Van Laar PJ, Cohen J. A prospective study of fever in the accident and emergency department. Clin Microbiol Infect 2003, 9:878-880. 10.1046/j.1469-0691.2003.00665.x, 14616713.
21. Moulin F, Raymond J, Lorrot M, Marc E, Coste J, Iniguez JL, Kalifa G, Bohuon C, Gendrel D. Procalcitonin in children admitted to hospital with community acquired pneumonia. Arch Dis Child 2001, 84:332-336. 10.1136/adc.84.4.332, 1718706, 11259234.
22. Gervaix A, Galetto-Lacour A, Gueron T, Vadas L, Zamora S, Suter S, Girardin E. Usefulness of procalcitonin and C-reactive protein rapid tests for the management of children with urinary tract infection. Pediatr Infect Dis J 2001, 20:507-511. 10.1097/00006454-200105000-00007, 11368108.
23. Schwarz S, Bertram M, Schwab S, Andrassy K, Hacke W. Serum procalcitonin levels in bacterial and abacterial meningitis. Crit Care Med 2000, 28:1828-1832. 10.1097/00003246-200006000-00024, 10890628.
24. Toikka P, Irjala K, Juven T, Virkki R, Mertsola J, Leinonen M, Ruuskanen O. Serum procalcitonin, C-reactive protein and interleukin-6 for distinguishing bacterial and viral pneumonia in children. Pediatr Infect Dis J 2000, 19:598-602. 10.1097/00006454-200007000-00003, 10917215.
25. Chan YL, Tseng CP, Tsay PK, Chang SS, Chiu TF, Chen JC. Procalcitonin as a marker of bacterial infection in the emergency department: an observational study. Crit Care 2004, 8:R12-R20. 10.1186/cc2396, 420058, 14975050.
26. Fernandez Lopez A, Luaces Cubells C, Garcia Garcia JJ, Fernandez Pou J, . Spanish Society of Pediatric Emergencies Procalcitonin in pediatric emergency departments for the early diagnosis of invasive bacterial infections in febrile infants: results of a multicenter study and utility of a rapid qualitative test for this marker. Pediatr Infect Dis J 2003, 22:895-903. 10.1097/01.inf.0000091360.11784.21, 14551491, Spanish Society of Pediatric Emergencies.
27. Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit Care 2010, 14:R15. 10.1186/cc8872, 2875530, 20144219.
28. Hedlund J, Hansson LO. Procalcitonin and C-reactive protein levels in community-acquired pneumonia: correlation with etiology and prognosis. Infection 2000, 28:68-73. 10.1007/s150100050049, 10782390.
29. Maisel A, Mueller C, Nowak R, Peacock WF, Landsberg JW, Ponikowski P, Mockel M, Hogan C, Wu AH, Richards M, Clopton P, Filippatos GS, Di Somma S, Anand I, Ng L, Daniels LB, Neath SX, Christenson R, Potocki M, McCord J, Terracciano G, Kremastinos D, Hartmann O, von Haehling S, Bergmann A, Morgenthaler NG, Anker SD. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 2010, 11:2062-2076.
30. Bello S, Lasierra AB, Mincholé E, Fandos S, Ruiz MA, Vera E, Ferrer M, Menendez R, Torres A. Prognostic power of proadrenomedullin in community-acquired pneumonia is independent on etiology. Eur Respir J 2011, 10. in press.
31. Potocki M, Breidthardt T, Reichlin T, Morgenthaler NG, Bergmann A, Noveanu M, Schaub N, Uthoff H, Freidank H, Buser L, Bingisser R, Christ M, Mebazaa A, Mueller C. Midregional pro-adrenomedullin in addition to b-type natriuretic peptides in the risk stratification of patients with acute dyspnea: an observational study. Crit Care 2009, 13:R122. 10.1186/cc7975, 2750172, 19627611.
32. Schuetz P, Christ-Crain M, Müller B. Biomarkers to improve diagnostic and prognostic accuracy in systemic infections. Curr Opin Crit Care 2007, 13:578-585. Review, 10.1097/MCC.0b013e3282c9ac2a, 17762239.
33. Karlsson S, Heikkinen M, Pettilä V, Alila S, Väisänen S, Pulkki K, Kolho E, Ruokonen E. Finnsepsis Study Group Predictive value of procalcitonin decrease in patients with severe sepsis: a prospective observational study. Crit Care 2010, 14:R205. 10.1186/cc9327, 3219988, 21078153.
34. Meng FS, Su L, Tang YQ, Wen Q, Liu YS, Liu ZF. Serum procalcitonin at the time of admission to the ICU as a predictor of short-term mortality. Clin Biochem 2009, 42:1025-1031. 10.1016/j.clinbiochem.2009.03.012, 19324026.
35. Lee YJ, Park CH, Yun JW, Lee YS. Predictive comparisons of procalcitonin (PCT) level, arterial ketone body ratio (AKBR), APACHE III score and multiple organ dysfunction score (MODS) in systemic inflammatory response syndrome (SIRS). Yonsei Med J 2004, 45:29-37.
36. Jeon EJ, Jung JW, Choi JC, Shin JW, Park IW, Choi BW, Park AJ, Kim JY. The value of procalcitonin and the SAPS II and APACHE III scores in the differentiation of infectious and non-infectious fever in the ICU: a prospective, cohort study. J Korean Med Sci 2010, 25:1633-1637. 10.3346/jkms.2010.25.11.1633, 2967001, 21060753.
37. Brunkhorst FM, Al-Nawas B, Krummenauer F, Forycki ZF, Shah PM. Procalcitonin, C-reactive protein and APACHE II score for risk evaluation in patients with severe pneumonia. Clin Microbiol Infect 2002, 8:93-100. 10.1046/j.1469-0691.2002.00349.x, 11952722.
38. Wang RL, Kang FX. Prediction about severity and outcome of sepsis by pro-atrial natriuretic peptide and pro-adrenomedullin. Chin J Traumatol 2010, 13:152-157.
39. Claessens YE, Mathevon T, Kierzek G, Grabar S, Jegou D, Batard E, Loyer C, Davido A, Hausfater P, Robert H, Lavagna-Perez L, Bernot B, Plaisance P, Leroy C, Renaud B. Accuracy of C-reactive protein, procalcitonin, and mid-regional pro-atrial natriuretic peptide to guide site of care of community-acquired pneumonia. Intensive Care Med 2010, 36:799-809. 10.1007/s00134-010-1818-4, 20232049.
40. Christ-Crain M, Stolz D, Bingisser R, Muller C, Miedinger D, Huber PR, Zimmerli W, Harbarth S, Tamm M, Muller B. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006, 174:84-93. 10.1164/rccm.200512-1922OC, 16603606.
41. Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, Muller B. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004, 363:600-607. 10.1016/S0140-6736(04)15591-8, 14987884.
42. Caruhel P, Mazier C, Kunde J, Morgenthaler NG, Darbouret B. Homogeneous time-resolved fluoroimmunoassay for the measurement of midregional proadrenomedullin in plasma on the fully automated system B.R.A.H.M.S KRYPTOR. Clin Biochem 2009, 42:725-8. 10.1016/j.clinbiochem.2009.01.002, 19318039.
43. Schuetz P, Chiappa V, Briel M, Greenwald JL. Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Arch Intern Med 2011, 171:1322-1331. 10.1001/archinternmed.2011.318, 21824946.
44. Hayashi Y, Paterson DL. Strategies for reduction in duration of antibiotic use in hospitalized patients. Clin Infect Dis 2011, 52:1232-1240. Review, 10.1093/cid/cir063, 21507920.
45. Jensen JU, Hein L, Lundgren B, Bestle MH, Mohr TT, Andersen MH, Thornberg KJ, Løken J, Steensen M, Fox Z, Tousi H, Søe-Jensen P, Lauritsen A, Strange D, Petersen PL, Reiter N, Hestad S, Thormar K, Fjeldborg P, Larsen KM, Drenck NE, Ostergaard C, Kjær J, Grarup J, Lundgren JD, . Procalcitonin And Survival Study (PASS) Group Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Crit Care Med 2011, 39:2048-2058. 10.1097/CCM.0b013e31821e8791, 21572328, Procalcitonin And Survival Study (PASS) Group.